Form 4 for ACRV Acrivon Therapeutics, Inc.
Accepted 2026-01-16 00:00:00 ET · period of report 2026-01-14 · accession 0000905148-26-000225 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-16 | 2026-01-14 | ACRV | Levy Adam D. | CFO | P - Purchase | $1.70 | +8,832 | 21.0K | +73% | +$15.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-14 | P | A | 8,832 | $1.70 | 20,983 | D | — | — | (F1) The price reported in Column 4 above reflects the weighted average purchase price. This transaction was executed in multiple trades at prices ranging from $1.695 to $1.7086, inclusive. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares purchased at each respective price within the range set forth in footnote 1 of this Form 4. |